Gallen International Breast Cancer Expert Conference [3, 4], BC is clinically divided into four subtypes: triple negative, hormone receptor (HR) negative and human epidermal growth factor receptor 2 (HER2) positive, HR positive and HER2 positive, HR positive, and HER2 negative. Here, ERBB2 is linked to breast carcinoma.